CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase II Study of Circulating Tumor DNA Directed Consolidation Durvalumab (MEDI4736) Following Induction and Concurrent Durvalumab with SABR for Stage I NSCLC. SCION: SABR and Checkpoint Inhibition of NSCLC

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT04944173
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:26:14.169984+00:00
Published At: 2024-09-03T00:00:00+00:00
Record Updated At: 2024-09-03
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Non Small Cell Lung Cancer", "Carcinoma, Non-Small-Cell Lung", "Non-small Cell Lung Cancer Stage I", "Lung Cancer", "Lung Cancer Stage I", "Lung Adenocarcinoma, Stage I", "Lung Squamous Cell Carcinoma Stage I"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2024-09-03"
protocolSection.identificationModule.nctId: "NCT04944173"
protocolSection.identificationModule.officialTitle: "A Phase II Study of Circulating Tumor DNA Directed Consolidation Durvalumab (MEDI4736) Following Induction and Concurrent Durvalumab with SABR for Stage I NSCLC. SCION: SABR and Checkpoint Inhibition of NSCLC"
protocolSection.statusModule.overallStatus: "WITHDRAWN"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.